Abstract: A process for producing a crosslinked cellulose ether including the steps of (i) contacting at least one cellulose material with a mixture comprising (ia) at least one crosslinking agent and (ib) at least one alkalization reagent to form an activated cellulose material; and (ii) contacting the activated cellulose material of step (i) with at least one etherification reagent; wherein the at least one etherification reagent reacts with the activated cellulose material to form the crosslinked cellulose ether; and a crosslinked cellulose ether produced by the above process.

Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the 5-HT4 receptor agonist in the manufacture of medicament intended for the treatment of the disorders described herein.

Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.

Abstract: Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.

Abstract: Among others, the present invention provides methods and compositions for controlling blood glucose or weight, including a combination of (i) a therapeutically effective amount of berberine (BBR), or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, including dihydroberberine (DHB); and (ii) vitamin B12. The combination effectively ameliorates BBR or DHB side effects, including VB12 reduction, gastrointestinal discomfort, and slowed bowel movements, by promoting transcobalamin II receptors synthesis, decreasing homocysteine levels and maintaining intestinal balance, including short chain fatty acids content, gut microbiota diversity and richness.

Abstract: The present invention relates to nutritional compositions comprising 2?-Fucosyllactose (2?FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Abstract: HIV pre-exposure prophylaxis (PrEP) has been available for nearly a decade. Patients can take a pill comprising of multiple antiviral agents that, if exposed to HIV, will prevent a permanent viral infection with an extremely high success rate. However, the use of PrEP antivirals has been linked to higher rates of STIs including HSV-1, HSV-2, Infectious Mononucleosis, chlamydia, gonorrhea, trichomanias, and syphilis. In particular, Herpes Simplex Viruses 1 and 2 can cause symptoms including oral or genital sores, while mono, caused by the Epstein-Barr Virus, can cause prolonged sickness. This disclosure utilizes two or more antiviral agents as a multi-use therapy for both suppressing a chronic herpesvirus infection while preventing an HIV infection. With this therapy, the odds of both acquiring HIV or spreading a herpesvirus are greatly reduced during human contact.

Abstract: The various aspects presented herein relate to processes for preparing food ingredients, flavors and sweeteners from extracts of plants that contain mogrosides such as Siraitia grosvenorii. Further provided herein are formulations and uses of compositions made from the processes.

Abstract: Provided is a Withania somnifera extract composition contains at least one of withaferin A, withanoside IV, withanoside V, withanoside VI, withanolide A, withanolide B, anaferine, anahygrine, 12-deoxywithastromonolide, sitoindoside X, sitoindoside IX, cuscohygrine, isopelletierine, bracteosin A, bracteosin B, or bracteosin C, or a salt or solvate of any one thereof. Related compositions, methods, and processes are also provided.

Abstract: The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers. (I), wherein X is O or NH.

Abstract: The present application provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma.

Abstract: Disclosed is a method of treating post-COVID condition(s) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Abstract: The invention is based on the discovery that combination therapy with 2-deoxyglucose, methotrexate, and wogonin provides a synergistic therapeutic effect in selectively killing cancer cells. Advantageously, the disclosed combinatorial therapy does not adversely affect normal, healthy cells. Although the individual compounds have been previously used in cancer treatment, the cited combination has been surprisingly found to selectively kill cancer cells, while not adversely affecting normal, healthy cells, especially those of the immune system. Further, the combination of the compounds produces a synergistic effect, with increased killing of cancer cells compared to each compound alone. Importantly, the combination caused the dying cancer cells to release three key markers of immunogenic cell death: HMGB1, ATP and calreticulin. Immunogenic cell death attracts and activates immune cells against cancers.

Abstract: The present invention relates to a lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids and a method for isolating and/or purifying nucleic acids.